Sunosi - (75, 150 mg; Tablet)

Generic Name	Solriamfetol Hydrochloride	Innovator	Axsome Therapeutics
Dosage	75, 150 mg; Tablet	Branded US Sales	Less Than $1000 mn
Probable FTF	More Than 5	Known Para IV Filers	More Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	SUNOSI is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*****	*** \ *********	*** **, ****	*******	****	***** *** **, ****
*********	*** \ *********	*** **, ****	*******	****	***** *** **, ****
******	*** \ *********	*** **, ****	*******	****	***** *** **, ****

Chronology Of Events